Copper therapy is aimed at removing excess accumulated copper and preventing its reaccumulation. Copper overload results in Wilson disease. Chelation therapy drugs approved for treating Wilson disease include penicillamine (Cuprimine® and Depen®) and trientine (Syprine® and Trientine Dihydrochloride) both of these drugs act by chelation or binding of copper, causing its increased urinary excretion.
Related Journals of Copper therapy
The international journal for inorganic, organometallic and bioinorganic chemistry, Scientific World Journal, Journal of Trace Elements in Medicine and Biology, The New England Journal of Medicine